A Phase II Study of Intermittent Gleevec® (Imatinib Mesylate) and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2017
Price : $35 *
At a glance
- Drugs Imatinib (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 30 May 2013 New trial record
- 10 Aug 2011 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 04 Apr 2010 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.